Novel therapy for liver cancer: direct intraarterial injection of a potent inhibitor of ATP production.
Most types of cancer are difficult to eradicate and some, like liver carcinomas, are almost always fatal. Significantly, we report here that direct intraarterial delivery of 3-bromopyruvate (3-BrPA), a potent inhibitorof cell ATP production, to liver-implanted rabbit tumors, inflicts a rapid, lethal blow to most cancer cells therein. Moreover, systemic delivery of 3-BrPA suppresses "metastatic" tumors that arise in the lungs. In both cases, there is no apparent harm to other organs or to the animals. Thus, intraarterial delivery of agents like 3-BrPA directly to the site of the primary tumor, followed by systemic delivery only when necessary, may represent a powerful new strategy for arresting the growth of liver and other cancers while minimizing toxic side effects.
Division of Cardiovascular and Interventional Radiology, The Russell H. Morgan Department of Radiology, The Johns Hopkins University School of Medicine, Baltimore, Maryland 21205-2185, USA.
Jean-Francois H
JF
Geschwind
Young H
YH
Ko
Michael S
MS
Torbenson
Carolyn
C
Magee
Peter L
PL
Pedersen
D000255:Adenosine Triphosphate / Q000037:antagonists & inhibitors / Q000096:biosynthesis; D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D002455:Cell Division / Q000187:drug effects; D002470:Cell Survival / Q000187:drug effects; D004621:Embolization, Therapeutic; D007269:Injections, Intra-Arterial; D008114:Liver Neoplasms, Experimental / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology / Q000628:therapy; D008175:Lung Neoplasms / Q000188:drug therapy / Q000473:pathology / Q000556:secondary; D009368:Neoplasm Transplantation; D011773:Pyruvates / Q000008:administration & dosage* / Q000009:adverse effects; D011817:Rabbits
D000970:Antineoplastic Agents; D011773:Pyruvates; C017092:bromopyruvate; D000255:Adenosine Triphosphate